NEW YORK (
CHANGE IN RATINGS
rated new Market Perform at BMO. $55 price target. Company is seeing slower domestic growth.
Brookfield Infrastructure Partners
rated new Neutral at Citigroup. $34 price target. Fully valued at current levels despite risk averse business model.
downgraded at Credit Suisse from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $21 price target.
downgraded to sell at TheStreet Ratings.
(FB - Get Report)
rated new Hold at Argus. Still uncertain how the company will monetize growth in mobile access.
rated new Hold at BGB Securities. $145 price target. Lower commodity prices and volatility could weigh on volumes.
Laboratory Corp. of America
rated new Buy at Canaccord. $100 price target. Company is a low-cost provider and volumes have likely troughed.
downgraded at Wells to Market Perform, Wells Fargo said. Estimates also cut, as the dollar remains an earnings headwind.
New Mountain Finance
initiated as hold at TheStreet Ratings.
rated new Buy at Deutsche. $58 price target. Kyprolis should be the company's next main growth driver.
Onyx Pharmaceuticals upgraded at Brean Murray from Hold to Buy. $60 price target. New cancer drug should be approved by the FDA next month.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Company is likely gaining market share from JCP, which could help boost sales growth.
downgraded at UBS to Neutral from Buy, UBS said. $105 price target. Stock run, high valuation, diminishing outperformance.
rated new Outperform at Credit Suisse. $48 price target. Company has strong market positioning and can deliver consistent organic growth.
downgraded at Citigroup to Sell from Neutral, Citigroup said. $56 price target. Near term pressures from declining fuel prices.
STOCK COMMENTS / EPS CHANGES
(ACN - Get Report)
estimates, target cut at BMO. Shares of ACN now seen reaching $66, according to BMO Capital. Estimates also reduced, given currency headwinds. Market Perform rating.
Bed, Bath & Beyond
(BBBY - Get Report)
estimates cut at Credit Suisse through 2014, Credit Suisse said. Comp sales have slowed down. Outperform rating and $91 price target.